healthNewsغير مصنف

Payers see price leverage with entry of Merck hepatitis C drug

(Reuters) – U.S. health insurers and pharmacy benefit managers expect the launch of Merck & Co Inc’s new hepatitis C pill to improve their leverage in price negotiations with drugmakers.

اظهر المزيد

مقالات ذات صلة

شاهد أيضاً
زر الذهاب إلى الأعلى